Axsome Therapeutics, Inc. (AXSM)
NASDAQ: AXSM · Real-Time Price · USD
207.78
-6.50 (-3.03%)
At close: Sep 18, 2026, 4:00 PM EDT
208.00
+0.22 (0.11%)
After-hours: Sep 18, 2026, 7:46 PM EDT
Axsome Therapeutics Stock Forecast
Stock Price Forecast
According to 21 analysts polled by S&P Global, Axsome Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $285.42. The average 1-year stock price forecast is 37.37% higher than the current stock price, while the lowest is $246 (+18.39%) and the highest is $380 (+82.89%).
Price Target: $285.42 (+37.37%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Axsome Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 17 | 17 | 17 | 17 | 17 | 17 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 21 | 21 | 21 | 21 | 21 | 21 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| RBC Capital | RBC Capital | Buy Maintains $297 | Buy | Maintains | $297 | +42.94% | Sep 18, 2026 |
| Piper Sandler | Piper Sandler | Buy Reiterates $258 | Buy | Reiterates | $258 | +24.17% | Sep 18, 2026 |
| BMO Capital | BMO Capital | Buy Reiterates $310 | Buy | Reiterates | $310 | +49.20% | Sep 14, 2026 |
| Mizuho Securities | Mizuho Securities | Buy Maintains $316 | Buy | Maintains | $316 | +52.08% | Sep 11, 2026 |
| Wells Fargo | Wells Fargo | Buy Maintains $256 | Buy | Maintains | $256 | +23.21% | Sep 10, 2026 |
Financial Forecast
Revenue This Year
966.22M
from 638.50M
Increased by 51.33%
Revenue Next Year
1.56B
from 966.22M
Increased by 61.67%
EPS This Year
-2.64
from -3.47
EPS Next Year
5.03
from -2.64
EPS and Forward PE are based on non-GAAP adjusted numbers.